These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38014511)

  • 21. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.
    Jagasia M; Zeiser R; Arbushites M; Delaite P; Gadbaw B; Bubnoff NV
    Immunotherapy; 2018 Apr; 10(5):391-402. PubMed ID: 29316837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
    Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
    Zhang MY; Zhao P; Zhang Y; Wang JS
    PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
    Cazeau N; Rodriguez S
    Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib.
    Cohen E; Bozonnat A; Battistella M; Calvani J; Vignon-Pennamen MD; Rivet J; Moins-Teisserenc H; Ta VA; Ram-Wolff C; Bouaziz JD; Mahevas T; Bagot M; Mourah S; Louveau B; Sicre de Fontbrune F; Peffault de Latour R; de Masson A; Battesti G
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e32-e34. PubMed ID: 37561935
    [No Abstract]   [Full Text] [Related]  

  • 29. Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease.
    Aslan Candır B; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Oncol Pharm Pract; 2022 Jun; 28(4):983-985. PubMed ID: 35019785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
    Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
    Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level.
    Modemann F; Ayuk F; Wolschke C; Christopeit M; Janson D; von Pein UM; Kröger N
    Bone Marrow Transplant; 2020 Dec; 55(12):2286-2293. PubMed ID: 32447349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updates in chronic graft-versus-host disease management.
    Malard F; Mohty M
    Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib for the treatment of graft-versus-host disease.
    Ali H; Salhotra A; Modi B; Nakamura R
    Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
    Martini DJ; Chen YB; DeFilipp Z
    Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
    Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
    Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib for Therapy of Graft-versus-Host Disease.
    Neumann T; Schneidewind L; Weigel M; Plis A; Vaizian R; Schmidt CA; Krüger W
    Biomed Res Int; 2019; 2019():8163780. PubMed ID: 30956985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease.
    De la Garza-Salazar F; Colunga-Pedraza PR; Coronado-Alejandro EU; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D
    Br J Haematol; 2023 May; 201(3):573-576. PubMed ID: 36859646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.